SweynTooth in Medical Devices

Part of our Bluetooth Low Energy security series for medical devices. For the full overview, start with BLE and Medical Device Cybersecurity.

SweynTooth is a family of BLE stack vulnerabilities that drew unusual joint attention from CISA and the FDA because pacemakers, glucose monitors, and other patient-connected devices were affected. For MedTech teams preparing a 510(k), De Novo, or PMA in 2026, it remains a useful case study for what the FDA now expects under Section 524B: SBOM-based component triage, clear VEX positions, and test evidence tied to realistic threat scenarios.

Key Takeaways

• SweynTooth exposed hidden risks in third-party BLE components.
• FDA expects detailed SBOMs and VEX for premarket submissions.
• Show how vulnerabilities impact device operation and patient safety.
• Test evidence must validate claims about component security.
• Implement practical mitigations for BLE, like secure pairing.
• Wireless stack failures necessitate both cybersecurity and safety plans.

Table of Contents

• Key Takeaways
• What SweynTooth Actually Is
• How SweynTooth Attacks Work
• What SweynTooth Teaches §524B Submitters
• Protecting Devices from SweynTooth-Class Issues
• Where Bluetooth Security Is Headed

Why this matters

The stakes involved with vulnerabilities like SweynTooth are exceptionally high for medical devices; a seemingly minor wireless communication flaw can translate directly into patient harm or death. A software or hardware component failure, induced by an exploit in a third-party BLE stack, can render devices inoperable, compromise patient data, or disrupt critical therapy delivery. The FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes this risk. It requires manufacturers to submit detailed Bill of Materials (SBOMs) and Vulnerability Exploitability eXchange (VEX) statements for premarket submissions. This guidance aligns with existing standards such as IEC 81001-5-1 for health software and devices, ISO 14971 for risk management, and AAMI TIR57 for principles for medical device security. Such documentation must clearly articulate how potential vulnerabilities, even within third-party components, are addressed. Manufacturers must demonstrate, through testing and analysis, that their devices maintain safety and essential performance despite the presence of known vulnerabilities, and that their mitigations are effective in all realistic attack scenarios. This moves beyond simple patch verification to a deeper analysis of impact and exploitability.

What SweynTooth Actually Is

SweynTooth is not a single bug. It is a set of vulnerabilities found in Bluetooth Low Energy implementations used by multiple chipset vendors and device manufacturers. Most of the issues sit in the BLE link layer, where malformed or unexpected packets can trigger crashes, deadlocks, denial of service, or other unsafe behavior.

That matters in medical devices because BLE is often treated as a convenience feature when it is really part of the device’s operational attack surface. If the wireless stack can be knocked over, patient monitoring, alarms, data transfer, pairing, or therapy support functions may also fail.

Why the Name Stuck

“SweynTooth” came from the researchers’ naming convention, referencing Sweyn Forkbeard. The name is memorable, but the practical lesson is supply-chain exposure. Many affected products inherited vulnerable BLE behavior from third-party SDKs and SoCs rather than from custom application code.

The Medical Device Problem

For consumer gadgets, a BLE crash is annoying. For a medical device, the same failure can become a safety issue. A radio stack failure can interrupt telemetry, block clinician access, delay data synchronization, or force the device into a degraded state that was never fully analyzed for security and safety impact.

That is exactly why SweynTooth still matters in premarket work. The FDA is not just looking for confirmation that a CVE was patched. Reviewers want to see that the manufacturer understood where the vulnerable component existed, whether the product was actually affected, what exploit conditions were realistic, and how residual risk was handled.

How SweynTooth Attacks Work

SweynTooth attacks generally rely on sending crafted BLE packets to a target running a vulnerable stack. Depending on the flaw, the device may crash, hang, stop responding, or enter an unintended state. In some cases, the result is denial of service; in others, the behavior can create a path to broader compromise.

BLE was designed for low-power, intermittent communication, which makes it a good fit for wearables, implanted devices, and home-use medical products. It also means many implementations were optimized for efficiency first. When vendors cut corners in packet handling, state management, or error recovery, security faults show up in exactly the places manufacturers assumed were handled safely by the chipset or SDK provider.

For medical device teams, the key point is simple: if your product includes BLE, the attack path does not end at “wireless present.” You need to map how malformed radio traffic affects device state, safety controls, logging, alarms, recovery behavior, and any downstream trust assumptions.

What SweynTooth Teaches §524B Submitters

SweynTooth is a good example of why checklist security fails. Saying “Bluetooth is encrypted” or “we use a reputable module” does not answer the questions the FDA is asking under §524B. You need evidence.

Start with Component-Level Visibility

If your device includes a BLE chipset, module, SDK, or third-party stack, it belongs in the SBOM at the right level of detail. That means enough specificity to support vulnerability correlation later. “Bluetooth library” is not useful. Vendor, component name, version, and dependency context are.

Once a SweynTooth-related CVE is identified, triage should answer four questions:

1. Is the affected component present in the shipped or supported configuration?
2. Is the vulnerable code path reachable in this product?
3. What is the clinical and operational impact if exploited?
4. What compensating controls, patches, or design constraints change exploitability?

That is where a VEX statement earns its keep. Not as paperwork, but as a concise technical position backed by traceable facts.

Show Your Threat Model, Not Just the CVE List

A premarket submission should connect the vulnerability to real system behavior. For SweynTooth, that usually means evaluating threats such as nearby unauthorized radio interaction, malformed packet injection during pairing or established sessions, disruption of telemetry, and forced device restart or lockup.

See also: De Novo Cybersecurity Requirements: What the FDA Expects, PMA Supplement vs Real-Time vs 30-Day Notice for Cybersecurity Changes, and FDA Penetration Testing Requirements for Medical Devices.

If the device can fail safely, say how. If it cannot, explain what controls prevent the exploit or reduce likelihood. The FDA will not be impressed by a vulnerability table that stops at severity scores. Reviewers want to see whether the issue changes the device’s security and safety profile in a meaningful way.

Test the Claim You Are Making

If your position is “not affected,” support it with architecture and version evidence. If your position is “affected but mitigated,” support it with test data. If your position is “patched,” show what changed and how you verified the fix.

That often includes:

• BLE fuzzing or malformed packet testing against exposed interfaces
• Verification of crash resistance, watchdog recovery, and safe-state behavior
• Confirmation that security logging captures the event where appropriate
• Regression testing to show the patch did not break pairing, telemetry, or therapy-supporting workflows
• Evidence that exploit preconditions are blocked by design, not assumed away

This is the difference between vulnerability management and submission-ready evidence.

Protecting Devices from SweynTooth-Class Issues

The first control is obvious but often incomplete: apply the vendor patch if one exists. The harder part is proving that the patch reached the actual fielded configuration and that it closed the problem without creating a new one.

Medical device manufacturers also need to resist the temptation to push all responsibility onto the chipset supplier. If the BLE stack is inside your product, it is your risk to assess, document, and validate.

Practical Mitigations

Several defensive steps help reduce exposure to SweynTooth-style flaws:

• Keep firmware, BLE stacks, and module SDKs current
• Remove unused Bluetooth features and services
• Require secure pairing and sane authentication flows
• Constrain radio behavior to the minimum necessary operating modes
• Monitor vendor advisories and maintain traceability from advisory to shipped product versions
• Verify recovery behavior after malformed traffic, not just confidentiality controls

For medical devices, add one more requirement: evaluate whether a wireless stack failure can create a hazardous situation. If so, the mitigation plan has to cover both cybersecurity and safety engineering.

Where Bluetooth Security Is Headed

SweynTooth was not the last BLE implementation problem, and it will not be the last inherited vulnerability from a third-party software component. What is changing is the level of scrutiny. The FDA, customers, and procurement teams increasingly expect manufacturers to show software transparency, faster vulnerability triage, and evidence that exploitability was evaluated in the context of the actual device.

That means stronger secure development practices for wireless features, tighter supplier management, and more disciplined validation of third-party components. It also means fewer hand-wavy claims about “industry-standard Bluetooth security” and more product-specific proof.

SweynTooth still earns attention because it exposed a pattern that shows up again and again in medical devices: hidden dependency risk, weak component traceability, and too little testing at the protocol boundary. Teams that fix those three problems are in much better shape for §524B submissions and for real-world security.

If your team needs help turning BLE vulnerability triage into submission-ready evidence, Blue Goat Cyber works with medical device manufacturers on penetration testing, product security assessments, and FDA-aligned cybersecurity documentation. Contact us for cybersecurity help.

How Blue Goat approaches this

Blue Goat Cyber assists medical device manufacturers in navigating complex cybersecurity requirements, including preparing for the FDA’s stringent premarket submissions. Our work in threat modeling, penetration testing, and gap analysis helps identify and remediate vulnerabilities stemming from third-party components, such as those exposed by SweynTooth. We develop precise SBOMs and actionable VEX statements and provide tailored test evidence to comply with the FDA's February 3, 2026 final guidance. Our team, comprised of CISSP and OSCP-certified experts, including ex-military red team personnel, brings practical, security-first methodologies to every engagement. We prioritize identifying exploitability and its impact on essential performance and safety. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at /services/fda-premarket-cybersecurity-services.

FAQ

What is SweynTooth?

SweynTooth is a collection of vulnerabilities found in Bluetooth Low Energy (BLE) implementations across various chipset vendors. These flaws primarily affect the BLE link layer, potentially causing device crashes, denial of service, or other unsafe behaviors.

Why does SweynTooth matter for medical devices?

A BLE vulnerability like SweynTooth in a medical device can lead to safety issues, such as interrupted patient monitoring, delayed data synchronization, or critical device function failures. The FDA expects manufacturers to understand and mitigate these risks thoroughly in premarket submissions.

What does the FDA expect regarding SweynTooth-like vulnerabilities?

Under its February 3, 2026 final guidance, the FDA expects manufacturers to provide a software bill of materials (SBOM) with component details, a Vulnerability Exploitability eXchange (VEX) statement explaining exploitability, and test evidence. This demonstrates how vulnerabilities are identified, assessed, and mitigated within medical devices.

How can manufacturers protect devices from SweynTooth-type issues?

Manufacturers should keep firmware and BLE stacks updated, remove unused Bluetooth features, require secure pairing, and constrain radio behavior. They must also monitor vendor advisories, trace components, and verify recovery behavior after malformed traffic.

Does patching a SweynTooth vulnerability fulfill FDA requirements?

Simply patching a vulnerability is not enough for the FDA. Manufacturers must provide evidence that the patch was correctly implemented, verify its effectiveness, and demonstrate that it did not introduce new problems. Testing should confirm crash resistance, watchdog recovery, and safe-state behavior.

Related: 20 Medical Device Protocols: Security Flaws, FDA Guidance, and Examples

About the author

Christian Espinosa, CISSP, Founder, Blue Goat Cyber. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. Read more about Christian.